Microport Cardioflow Medtech Corp
HKEX:2160
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Microport Cardioflow Medtech Corp
HKEX:2160
|
CN |
|
S
|
SalMar ASA
XBER:JEP
|
NO |
|
G
|
Galvo SA
WSE:GAL
|
PL |
|
Akobo Minerals AB (publ)
OTC:AKOBF
|
SE |
Microport Cardioflow Medtech Corp
MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-02-04. The firm is mainly engaged in the development and commercialization of transcatheter and surgical solutions for valvular heart diseases. The firm's main products include the first-generation transcatheter aortic heart valve implantation (TAVI) product VitaFlow and the second-generation TAVI product VitaFlow II. The firm mainly conducts business within the domestic market.
MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-02-04. The firm is mainly engaged in the development and commercialization of transcatheter and surgical solutions for valvular heart diseases. The firm's main products include the first-generation transcatheter aortic heart valve implantation (TAVI) product VitaFlow and the second-generation TAVI product VitaFlow II. The firm mainly conducts business within the domestic market.
